Nuclear hormone receptors as therapeutic targets

Moshe Levi, Xiaoxin Wang, Devasmita Choudhury

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Scopus citations


In spite of excellent glucose and blood pressure control, including administration of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, diabetic nephropathy (DN) still develops and progresses. The development of additional protective therapeutic interventions is, therefore, a major priority. Nuclear hormone receptors regulate carbohydrate metabolism, lipid metabolism, the immune response, inflammation and development of fibrosis. The increasing prevalence of DN has led to intense investigation of the role that nuclear hormone receptors may have in slowing or preventing the progression of renal disease. Several nuclear receptor-activating ligands (agonists) have been shown to have a renal protective effect in the context of DN. This review will discuss the evidence regarding the beneficial effects of the activation of the vitamin D receptor (VDR) and the farnesoid X receptor (FXR) in preventing the progression of DN, and will describe how the discovery and development of compounds that modulate the activity of VDR and FXR may provide potential additional therapeutic approaches in the management of DN.

Original languageEnglish (US)
Title of host publicationDiabetes and The Kidney
EditorsKar Neng Lai, Sydney Tang
Number of pages8
StatePublished - Jun 2011

Publication series

NameContributions to Nephrology
ISSN (Print)0302-5144

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Nuclear hormone receptors as therapeutic targets'. Together they form a unique fingerprint.

Cite this